New "Blockbusters" Will Triple Acute Coronary Syndrome Market

July 29, 2014
The Pharm Exec staff

Pharmaceutical Executive

The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.

The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.

The company’s latest report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) three monoclonal antibodies (mAbs), all PCSK9 inhibitors, have the potential to reshape the post-ACS, dyslipidemia landscape.

Amgen’s evolocumab, Sanofi and Regeneron’s alirocumab, and Pfizer’s bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, it is reported; it is expected that these treatments to be launched in the middle of the forecast period. GlobalData’s Eric J. Dimise, Ph.D, forecasts that these treatments “will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion.”

GlobalData has also identified two new anticoagulants, Janssen’s Xarelto and Merck’s Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years.

Dimise states that Xarelto, when approved for the ACS indication in the US by 2018, will result in peak-year sales approaching $8 billion for ACS alone, while Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015.